Ildong announces combination product license agreement with Ajinomoto

Published: 2012-10-31 06:58:00

Updated: 2012-10-31 06:58:00

Ildong Pharm last Thursday announced that it has entered into a commercial license agreement with Ajinomoto Pharmaceutical Co. to market a combination drug containing cilnidipine and valsartan in Korea.

Ildong is expected to launch the combination drug in 2015 after carrying out clinical trial...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK